Rhodium-105 tetrathioether complexes: radiochemistry and initial biological evaluation.
105Rhodium(III) complexes with three different acyclic tetrathioether ligands containing pendant carboxylic acid groups have been synthesized and characterized. The complexes were evaluated for stability under physiological conditions and the most promising complexes were evaluated in vivo in normal mice. The primary route of clearance for these complexes was the renal/urinary system, consistent with the presence of pendant carboxylate groups. The results indicate that the cis-[Rh(III)Cl2(2,5,8,11-tetrathiadodecane-1,12-dicarboxylic acid)]+ complex shows the most promising in vivo characteristics on which to base a potential therapeutic radiopharmaceutical.
Goswami
N
N
Department of Chemistry, University of Missouri, Columbia 65211, USA.
Higginbotham
C
C
Volkert
W
W
Alberto
R
R
Nef
W
W
Jurisson
S
S
D000818:Animals; D006863:Hydrogen-Ion Concentration; D007202:Indicators and Reagents; D007553:Isotope Labeling; D008024:Ligands; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D009942:Organometallic Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics; D011868:Radioisotopes; D019275:Radiopharmaceuticals / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics; D012238:Rhodium / Q000737:chemistry*; D013440:Sulfides / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics; D014018:Tissue Distribution
D007202:Indicators and Reagents; D008024:Ligands; D009942:Organometallic Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D013440:Sulfides; C406249:dichloro(2,5,8,11-tetrathiadodecane-1,12-dicarboxylic acid)rhodium(III); D012238:Rhodium